Horn Margaret A sold $15.0M of RVMD

Horn Margaret A (Chief Operating Officer) sold 93,575 shares of Revolution Medicines, Inc. (RVMD) at an average of $160.00 ($156.12–$160.17, $14.97M total) across 3 trades over 2025-06-16 to 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Horn Margaret A
Published Jun 17, 2026, 11:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 11:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RVMD
Neutral
medium confidence
Mentioned
$RVMD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDNeutralLow
01

Why it matters

The disclosure provides a concrete, time-stamped insider selling event (~$14.97M) that can influence short-term sentiment, though 10b5-1 typically limits the signal of new negative information.

02

Market read

Traders may monitor for follow-on insider activity or correlate with upcoming company catalysts, but the filing alone is unlikely to drive a major repricing.

03

What to watch

The trades span multiple dates; the market may already have priced any earlier sale activity, leaving only the incremental effect of the latest filing.

Relevance 6/10Novelty 5/10Timing: Filed 2026-06-17 (after-hours/late day) for trades dated 2025-06-16 to 2026-06-17

Background

This is an SEC Form 4 insider transaction filing for Revolution Medicines, Inc., reporting officer (COO) share sales executed in open-market trades under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$RVMDNeutralMedium confidence
Context

Revolution Medicines COO Margaret A Horn sold ~$15.0M of RVMD shares in open-market transactions under a 10b5-1 plan, per SEC Form 4.

Expected impact

Likely limited immediate price impact; any reaction should be modest unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing discloses a large dollar-value sale by an officer, yet it is explicitly under a pre-arranged 10b5-1 plan, which typically dampens inference about new negative information.

Market effects

No direct sector read-through; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity/compensation mechanics rather than a change in fundamentals.

Key entities

  • Revolution Medicines, Inc.

    Subject of the Form 4 insider transaction; COO sold 93,575 shares for ~$14.97M under a 10b5-1 plan.

  • Horn Margaret A

    COO who executed the open-market sales; holdings after transaction reported as 154,647 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RVMDMedAI 8/10

Why is Revolution Medicines stock surging today?

Revolution Medicines (RVMD) stock rose 7% after reporting Q3 revenue of $197.6M, exceeding estimates, driven by its new drug RASONQUE. Analysts raised price targets, with HC Wainwright setting a $350 target. The company has strong cash reserves and reaffirmed its 2026 expense guidance. NASDAQ and S&P 500 gains provided a supportive market backdrop.

$RVMDMed

Revolution Medicines Inc (RVMD) Q3 2026 Earnings Call Highlights: RASONQUE's Blockbuster

Revolution Medicines (RVMD) reported $198M in first-month sales for RASONQUE, with inventory levels managed at two weeks. Prescriptions were split 40% academic and 60% community. The company expects payer coverage to evolve, with reimbursement currently strong. RASonate 312 trial is ongoing, and the company is exploring broader colorectal cancer opportunities. Management declined to comment on October trends, citing early launch stage.

$RVMDHigh

Revolution Medicines (RVMD) Q3 2026 Earnings Call Transcript

Revolution Medicines (RVMD) reported $198M in Q3 2026 revenue from its newly approved drug, RAZONQ, for metastatic pancreatic cancer. The FDA approved the drug in August, and the NCCN guidelines expanded its recommended use. The company is preparing for international expansion and has received positive opinions from the EMA. RAZONQ is also being studied for non-small cell lung cancer.

$RVMDMed

What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call

Revolution Medicines (RVMD) reported Q3 earnings, highlighting RASONQUE's reimbursement progress, regulatory updates, and pipeline advancements. RASONQUE is included in NCCN guidelines for pancreatic cancer. The company expects European and potential Japanese launches. Q3 revenue included initial stocking, with R&D expenses rising to $417.1M. RVMD ended the quarter with $3.7B in cash. The company reiterated 2026 operating expense guidance and anticipates higher 2027 expenses.

$RVMDHighAI 9/10

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines, Inc. (RVMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress · Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic th